New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 13, 2014
05:21 EDTALNY, SNYAlnylam, Genzyme form transformational alliance for RNAi therapeutics
Alnylam Pharmaceuticals (ALNY) and Genzyme, a Sanofi company (SNY), announced that they have formed a transformational alliance for the development and commercialization of RNAi therapeutics as genetic medicines. Alnylam will retain product rights in North America and Western Europe, while Genzyme will obtain the right to access Alnylam’s current “5x15”1 and future genetic medicines pipeline in the rest of the world, or ROW, including global product rights for certain programs. In addition, Genzyme becomes a major Alnylam shareholder through an upfront purchase of $700M of newly issued stock at approximately $80/share, representing an approximately 12% ownership position. This alliance significantly bolsters Alnylam’s balance sheet to over $1B in cash, enabling an increased investment in the company’s RNAi therapeutics pipeline and is expected to secure Alnylam’s financial independence through to multiple product launches. Upon the closing of the transaction, Genzyme will opt-in to patisiran, or ALN-TTR02, – an RNAi therapeutic currently in a Phase 3 trial for the treatment of transthyretin, or TTR-mediated amyloidosis, or ATTR patients with Familial Amyloidotic Polyneuropathy – for its ROW territories, while Alnylam retains full product rights in North America and Western Europe. Alnylam and Genzyme have also agreed to expand their current collaboration on ALN-TTRsc – an RNAi therapeutic currently in a Phase 2 trial for the treatment of ATTR patients with TTR amyloid cardiomyopathy – where the parties will co-develop and co-promote ALN-TTRsc in North America and Western Europe; Alnylam will maintain development and commercialization control with ALN-TTRsc and Genzyme will develop and commercialize the product in its ROW territories. The companies believe that this broadened collaboration on ALN-TTRsc will increase the product’s overall value, as significant market development and commercial operational scale is warranted to maximize the opportunity for both familial cardiac amyloidosis senile systemic amyloidosis manifestations of TTR cardiac amyloidosis.
News For ALNY;SNY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 1, 2015
11:41 EDTSNYSanofi downgraded to Equal Weight from Overweight at Morgan Stanley
08:38 EDTSNYSanofi launches 24-count tablet pack of Priftin for LTBI
Subscribe for More Information
07:46 EDTSNYFDA and the Parental Drug Association to co-host a conference
Subscribe for More Information
06:15 EDTSNYUnitedHealth unit prefers Sanofi, Regeneron cholesterol shot, Bloomberg says
Subscribe for More Information
November 30, 2015
08:28 EDTSNYSanofi has a conference call hosted by JPMorgan
Subscribe for More Information
08:16 EDTSNYPieris Pharmaceuticals achieves payment milestone in Sanofi collaboration
Subscribe for More Information
07:47 EDTALNYLeerink positive on Alnylam, Juno, Karyopharm into ASH meeting
Subscribe for More Information
November 29, 2015
19:37 EDTSNYSanofi working with Lazard to explore sale of animal health unit, Reuters says
Lazard (LAZ) is working with Sanofi (SNY) to prepare a sale or listing of the company's Merial animal health division, which could value the unit at up to $12.7B, reports Reuters, citing sources. The investment bank is expected to land the lead advisory role for the potential deal, sources told Reuters, which added that the sale would play a "pivotal role" in getting Sanofi "back on track." Reference Link
November 24, 2015
05:23 EDTSNYSanofi, Regeneron announce Praluent ODYSSEY OUTCOMES trial enrollment complete
Subscribe for More Information
November 20, 2015
06:09 EDTSNYSanofi, AstraZeneca to exchange more than 210,000 compounds
Subscribe for More Information
November 18, 2015
08:11 EDTSNYIMS Health forecasts global drug spending to increase 30% by 2020 to $1.4T
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use